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Background and Objective. Prospective studies have
shown that high plasma levels of fibrinogen are inde-
pendently associated with the risk of cardiovascular
complications. In patients suffering from peripheral
vascular disease (PVD) fibrinogen has been shown to
be an independent predictor of cardiovascular dis-
ease but its determinants have never been exam-
ined in this clinical setting.
Design and Methods. Fibrinogen levels were related
to clinical and laboratory variables in 2,111 patients
suffering from PVD. We also analyzed whether there
was a regional distribution of risk factors.
Results. The median values of fibrinogen was 312
mg/dL. The clinical variables examined did not dif-
ferentiate patients with elevated or normal fibrinogen
levels. In particular, patients with ankle/arm pres-
sure ratio < 0.8 did not show a higher prevalence of
fibrinogen > 312 mg/dL. Conversely, white blood cell
(WBC) count and serum cholesterol levels were sig-
nificantly associated with high fibrinogen levels
(p<0.0001). Multiple logistic regression analysis
demonstrated that areas of Italy were differently
associated with high plasma fibrinogen levels
(p<0.03): subjects in the north and middle of Italy
having significantly higher values of fibrinogen than
subjects in the south of Italy (p<0.01). A similar
regional distribution was observed for WBC count
and serum cholesterol levels.
Interpretation and Conclusions. The regional distrib-
ution of risk factors raises the question as to
whether the already reported large variability of car-
diovascular events so in PVD may be attributed to a
non homogeneous distribution of risk factors.
©1998, Ferrata Storti Foundation
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Several prospective studies provided evidencethat a high fibrinogen level is an independentpredictor of cardiovascular complications and
that fibrinogen may play an important role in the
pathogenesis of atherosclerosis.1-5 In the setting of
peripheral vascular disease (PVD), fibrinogen values
have been reported to be increased and to predict
the re-occlusion of femoro-popliteal vein grafts.6
These data has been recently supported by a large tri-
al performed in an Italian population suffering from
claudication (ADEP study).7 In this study, which
included over 2,000 patients with PVD, plasma
fibrinogen was shown to be an independent predic-
tor of all cardiovascular events. Also, dividing the
vascular events according to the circulatory area,
plasma fibrinogen was shown to predict in particu-
lar cerebro-vascular events such as stroke and tran-
sient ischemic attacks.8
Several factors may influence plasma fibrinogen;
they include age, alcohol consumption, social class,
obesity, serum cholesterol, diabetes mellitus, smok-
ing, white cell count.5 It is plausible that the above
reported determinants are also important in patients
with PVD, but, until now, data exploring this partic-
ular issue are not available.  
We took advantage of the availability of data deriv-
ing from the ADEP study to retrospectively investi-
gate whether or not the determinants of fibrinogen in
PVD are similar to those previously reported.  Also,
since the Italian centers were a priori selected in the
north, middle and south of Italy, we investigated
whether there was a regional difference in the distri-
bution of fibrinogen as well as other risk factors for
atherosclerosis.
Materials and Methods
Subjects
The present study was carried out in patients suf-
fering from PVD enrolled in an Italian double blind,
randomized, multicenter trial, stratified by center,
planned to assess the therapeutic effect of pico-
tamide.9,10 All patients were recruited between Janu-
ary 1989 and August 1989 as reported elsewhere.7
One hundred and twenty Italian centers participated
in the study. The enrollment of patients started on
January 1st, 1989, and closed on August 30th, 1989.
During this period, 2,304 patients were recruited.
During the study, 116 patients were lost to follow-up
and  77 were withdrawn from the trial because of side
effects. Therefore, the on-treatment group was com-
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posed of 2,111 PVD patients (347 females and 1,764
males, aged from 40 to 78 years).
Study design and methods
Several factors known to influence fibrinogen lev-
els5 were considered in this study; in addition all the
risk factors for the cardiovascular complications in
PVD patients were included as possible determinants
of high fibrinogen levels.8 All the factors considered
are listed in the rest of the paragraph.
Smokers were defined as patients smoking at least
five cigarettes a day. Hypertension was defined as a
blood pressure higher than 140/90 mmHg measured
on at least 2 different days  while the patient was at
rest for at least 10 min. Patients with a blood pressure
lower than the cut-off point but on medical therapy
for hypertension were also considered hypertensives.
Diabetes was defined as the use of insulin or oral
hypoglycemic drugs. A positive history of vascular
surgery was when the patient has had an endarterec-
tomy, aorto-coronary bypass, angioplasty, femoro-
iliac or femoro-popliteal bypass or peripheral angio-
plasty. Ankle/arm pressure ratio was defined as
abnormal if less than 0.8.8
During the randomization phase and throughout
the follow-up, which lasted 18 months, many meet-
ings were carried out between the researchers partici-
pating in the study. In order to facilitate the meetings
it was decided a priori that researchers from the centers
in the north (Piemonte, Valle d'Aosta, Lombardia, Li-
guria, Veneto, Trentino, Friuli), middle (Toscana,
Emilia Romagna, Abruzzo, Marche, Umbria, Lazio)
and south (Puglia, Sardegna, Campania, Sicilia, Cal-
abria) of Italy would meet separately. The rate of
enrolment from January to August was equally dis-
tributed between the areas of Italy. The baseline lab-
oratory findings were used for the statistical analysis.
Blood samples were taken between 8.00 and 9.00
a.m. from patients who had fasted for at least 12h
and sent for analysis to the local laboratory of each
centre. The following variables were measured for each
sample: white blood cell (WBC) count (3109 cells/L),
hematocrit (%), cholesterolemia (mg/dL) and triglyc-
eridemia (mg/dL). Fibrinogen plasma levels were mea-
sured by the Clauss method11 in 95% of patients. Stan-
dardization of the laboratory data was performed as
previously described.8
The major events taken into consideration during
the ADEP study were: (a) vascular and non-vascular
death, (b) fatal and non-fatal myocardial infarction
(MI), (c) fatal and non-fatal stroke, (d) amputation
above the ankle for reasons other than tumor or trau-
ma, and (e) surgery for ischemic viscera. Minor events
included: (a) recently developed angina or unstable
angina, (b) possible or probable MI, (c) transient
ischemic attacks (TIA), (d) minor stroke, (e) recent-
ly developed renal failure, (f) hypertension, and (g)
deterioration of vascular disease leading to surgical
intervention, angioplasty or local thrombolysis. The
occurrence of any of the above minor events did not
require treatment discontinuation. If a patient had
both a minor and a major event, only the latter was
counted; each patient contributed only one event.
Statistical analysis
Statistical analysis was performed by chi-square
statistics and by ANOVA and appropriate multiple
comparisons test. When necessary, log transforma-
tion was used to normalize the data, or appropriate
non-parametric tests were employed.  In particular,
skewness in the distribution of fibrinogen (mean±SD:
329±89 mg/dL; range: 31-819 mg/dL) was dimin-
ished by truncation on the median value of the whole
population (312 mg/dL). To determine the variables
capable of being independently predictive of high
fibrinogen values (more than 312 mg/dL) a multiple
logistic regression analysis was done. The laboratory
variables (such as: fibrinogen, total cholesterol, try-
glicerides, WBC count, hematocrit) and age were
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Table 1. Clinical and laboratory characteristics of PVD
patients divided according to fibrinogen levels.
Patients with Patients with
fibrinogen plasma p value fibrinogen plasma
levels ≤ 312 mg/dL levels >312 mg/dL
(n=1110) (n=1001)
Males
n (%) 921 (83) NS 843 (84)
Age (years) (range)
63±8 (40-78) NS 63±7 (40-75)
Ankle/arm pressure ratio < 0.8
n (%) 517 (47) NS 504 (50)
Smoking
n (%) 373 (34) NS 344 (34)
Hypertension
n (%) 380 (34) NS 365 (36)
Diabetes
n (%) 207 (19) NS 190 (19)
High white blood cell count (> 7.0x109 cells/L)
n (%) 451 (41) <0.0001 546 (55)
High hematocrit (>43.5%)
n (%) 536 (48) NS 498 (50)
High total cholesterol (>220 mg/dL)
n (%) 482 (43) <0.0001 526 (53)
High triglycerides (>149 mg/dL)
n (%) 536 (48) NS 516 (52)
Italian region
n (%) <0.01*
North 318 (29) 331 (33)
Middle 458 (41) 427 (43)
South 334 (30) 243 (24)
*p values refer to trends in proportions. The subdivision of the chi-square
statistic is the following: north vs. middle, p>0.05; north vs. south, p<0.01;
middle vs. south, p<0.02.
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coded on the median value of whole series of
patients. Italian areas were coded as north (including
7 Italian regions), middle (including 6 Italian regions)
and south (including 5 Italian regions). Data are pre-
sented as mean±standard deviation. Only two-tailed
probabilities were used for testing statistical signifi-
cance. A p value < 0.05 was regarded as statistically
significant.12 All calculations were made using a per-
sonal computer software (Stat View II by Abacus
Concepts, Berkeley, CA and EGRET by SERC, Seattle,
Wash., USA).
Results
In the whole PVD population the median value of
plasma fibrinogen was 312 mg/dL (mean±SD:
329±89 mg/dL); one thousand and one patients
(47%) had fibrinogen values higher than 312 mg/dL.
Table 1 reports the clinical and laboratory variables
associated with high fibrinogen values. Sex, age, hyper-
tension, smoking, diabetes and high hematocrit values
did not differentiate patients with fibrinogen > or ≤
312 mg/dL. The concentration of fibrinogen was not
related to the severity of atherosclerosis. Thus, in
patients with ankle/arm pressure ratio below 0.8,
which identifies the patients with more severe PVD,
we did not observe a higher prevalence of elevated val-
ues of fibrinogen.
Among the laboratory indices, high WBC count
and serum cholesterol were significantly associated
with high values of fibrinogen; 55% and 53% of
patients with fibrinogen > 312 mg/dL also had high
values of WBC count and serum cholesterol, respec-
tively. Intriguingly, we also found a different distrib-
ution of fibrinogen values in the 3 areas of Italy. Thus,
there was a significantly lower percentage (24%) of
patients with high fibrinogen values in the south of
Italy than in middle Italy (43%) and north of Italy
(33%). Logistic regression analysis (Table 2) was used
to model the relationship between the above men-
tioned variables and high fibrinogen levels.  This
analysis confirmed that high WBC count, high serum
cholesterol and areas of Italy were independently
related to high fibrinogen values. When the prog-
nostic variables were used in a stepwise regression
analysis we obtained similar results; in fact, the inde-
pendent predictors of high plasma fibrinogen values
were only high WBC count (coefficient = 0.53, SE =
0.09, OR = 1.70, 95% confidence limits = 1.42-2.02,
p<0.001), high total cholesterol (coefficient = 0.30,
SE = 0.09, OR = 1.35, 95% confidence limits = 1.13-
1.61, p<0.001), and areas of Italy (coefficient = 0.13,
SE = 0.06, OR = 1.14, 95% confidence limits = 1.0-
1.28, p=0.029).
The different distribution of fibrinogen values in the
3 areas of Italy prompted us to analyze further the
clinical laboratory characteristics of the PVD popula-
tions in the south, middle and north of Italy (Table 3).
We found a higher percentage of patients with severe
atherosclerosis in north and middle Italy than in the
south of Italy. Thus, in north and middle Italy, there
was a higher prevalence of patients with ankle/arm
pressure ratio <0.8 (north=56%, middle=50%,
south=38%, p<0.0001) and previous vascular surgery
(north=36%, middle=29%, south=19%, p<0.0001).
Conversely, diabetes was significantly more prevalent
in the south than north and middle Italy (p<0.001).
Three laboratory variables demonstrated a clear
regional distribution; plasma fibrinogen, WBC count
and serum cholesterol levels. Thus, the prevalence of
high values of fibrinogen, WBC count and serum cho-
lesterol was significantly lower in the south than mid-
dle and north of Italy, with the exception of WBC
count which was not significantly different between
middle and south Italy (Table 3). Similar findings were
obtained after excluding patients with more severe
atherosclerosis. Thus, in patients without previous
vascular surgery and ankle/arm pressure ratio >0.8
(n=808) we observed again that fibrinogen and serum
cholesterol have a regional distribution with the low-
est percentage of high values occurring in the south of
Italy (Table 4); WBC count was higher in the north
compared to middle and south but, again, there was
no difference between middle and south Italy.
During 18 months of follow-up, 246 (12%) PVD
patients had cardiovascular events. As shown in
Table 5, in the south there was a significantly lower
percentage of cardiovascular events than in the  north
or middle of Italy (p<0.02). After excluding patients
without vascular surgery and ankle/arm pressure
Table 2. Logistic regression analysis (full model) of high
fibrinogen plasma values (>312 mg/dL) in the whole PVD
series.  Codes are 0 for No, 1 for Yes. Areas of Italy are coded
as 0 for south, 1 for middle and 2 for north of Italy.
Determinant Regression Standard Odds 95%
coefficient error ratio confidence p
(b) se (b) limits
Constant -0.81 0.16 0.4 0.3-0.6 <0.001
Male 0.07 0.12 1.1 0.8-1.4 NS
Hypertension 0.1 0.09 1.1 0.9 -1.3 NS
Smoking -0.03 0.09 1.0 0.8-1.2 NS
Diabetes 0.04 0.11 1.0 0.8-1.3 NS
Index < 0.8 0.10 0.09 1.1 0.9-1.3 NS
Areas of Italy 0.12 0.06 1.13 1.0-1.3 =0.044
High WBC count 0.53 0.09 1.69 1.4-2.0 <0.001
High hematocrit -0.02 0.09 1.0 0.8-1.2 NS
High total cholesterol 0.31 0.09 1.36 1.1-1.6 <0.001
High triglycerides 0.02 0.09 1.0 0.8-1.2 NS
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ratio more than 0.8, from north to south there was
a progressive decrease of cardiovascular events but
this data was not significant probably because of the
small number of patients included in this analysis.
Discussion
This study provides evidence that ,also in the set-
ting of PVD, fibrinogen is influenced by several factors
which have already been demonstrated to affect it in
a healthy population or other clinical settings.  Thus,
fibrinogen was significantly associated with WBC
count and serum cholesterol. Surprisingly, no signif-
icant association was observed with smoking, which
is considered to strongly influence fibrinogen. How-
ever, this influence has been derived prevalently from
studies performed in healthy populations, therefore
it cannot be excluded that in patients with overt ath-
erosclerosis smoking may play a minor role. Howev-
er, in our study smoking habit was not confirmed by
a verification test. It has been demonstrated that
smoking’s effect on fibrinogen is dose related13 and
that fibrinogen and carboxyhemoglobin levels are sta-
tistically correlated.14 Further study, therefore, is nec-
essary to explain our data.
We also sought to analyze whether the plasma lev-
els of fibrinogen were related to the severity of ather-
osclerosis. The ankle/arm pressure ratio is an index
which is quite sensitive indicator of the degree of
peripheral vascular disease15 and is predictor of car-
diovascular complications.8,16 Patients with an
ankle/arm pressure ratio below 0.8, which identified
those with more severe atherosclerosis,17 did not show
Table 3. Regional distribution of clinical and laboratory characteristics of PVD patients.
North p value Middle p value South p value
(n=649) (n=885) (n=577) North vs. South
Ankle/arm pressure ratio < 0.8 n (%) 364 (56) <0.002 440 (50) <0.0001 217 (38) <0.0001
p<0.0001
Previous vascular surgery n (%) 235 (36) <0.002 254 (29) <0.0001 112 (19) <0.0001
p<0.0001
Diabetes n (%) 141 (24) NS 15 (17) <0.001 105 (17) <0.001
p<0.001
High fibrinogen (>312 mg/dL) n (%) 331 (51) NS 427 (48) <0.03 243 (42) <0.002
p<0.01
High white blood cell count n (%) 348 (54) <0.001 392 (44) NS 257 (45) <0.002
(>7.03109 cells/L) p<0.001
High hematocrit n (%) 336 (52) <0.02 405 (46) NS 293 (51) NS
(>43.5%)  p<0.04
High total cholesterol n (%) 372 (57) <0.001 413 (47) <0.003 223 (39) <0.0023
(>220 mg/dL)  p<0.0001
Table 4. Regional distribution of clinical and laboratory characteristics of PVD patients without previous surgery and with an
ankle-arm index more than 0.8.
North p value Middle p value South p value
(n=189) (n=323) (n=296) North vs. South
Diabetes n (%) 75 (25) NS 60 (19) <0.01 27 (14) NS
p<0.01
High fibrinogen n (%) 103 (54) NS 150 (46) NS 120 (41) <0.01
(>312 mg/dL)  p<0.02
High white blood cell count n (%) 98 (52) <0.01 129 (40) NS 134 (45) <0.01
(>7.03109 cells/L)  p<0.04
High hematocrit n (%) 97 (51) NS 160 (50) NS 149 (50) NS
(>43.5%) NS
High total cholesterol n (%) 121 (64) <0.01 159 (49) <0.05 122 (41) <0.01
(>220 mg/dL)   p<0.0001
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a higher prevalence of elevated plasma levels of
fibrinogen suggesting that the severity of atheroscle-
rosis does not affect fibrinogen values. The relation-
ship between fibrinogen and degree of atherosclero-
sis has already been studied in other clinical settings
such as coronary and cerebral vascular diseases but
the results are conflicting since not all the studies
reported that fibrinogen levels are related to the sever-
ity of atherosclerosis.18-21 The use of more sensitive
instrumental approaches to screen for the degree of
vascular disease is needed to solve this issue.
The intriguing information of our study is that dif-
ferent areas of Italy are differently associated with
fibrinogen levels. Thus in the south of Italy fibrinogen
values were lower than in the middle and north. We
could exclude at least 3 factors which might poten-
tially bias this finding. The most important was the
randomization period since it is known that fibrino-
gen has seasonal variations with higher values during
the winter.22 The randomization period of this study
lasted 8 months with no significant difference of ran-
domisation time among the 3 areas. The second
potential bias was the method of measuring fibrin-
ogen, which could vary among the centres involved in
the study. However, 95% of centres used the Clauss
method to measure fibrinogen. The third potential
bias could result from a posteriori division of the coun-
try areas with an ensuing elimination of potential con-
founding factors. This possibility was excluded by the
fact that we defined ab initio the areas which were to
be considered as components of north, middle and
south of Italy. Multiple logistic regression analysis
confirmed that areas of Italy were independently asso-
ciated with high plasma fibrinogen values so indicat-
ing that in the south of Italy there are some determi-
nants which may contribute to lower fibrinogen lev-
els. There are theoretically 3 determinants which may
reduce fibrinogen in the south of Italy. One factor
could be the temperature which is higher in this area
of Italy and could affect the fibrinogen concentration
as a consequence of a reduced rate of infections or
chronic inflammation. Diet may be another impor-
tant element, since, for instance, it is known that a
Table 5. Regional distribution of cardiovascular events during the follow-up.
North p value Middle p value South p value
North vs. South
All patients (n=649) (n=885) (n=577)
Cardiovascular events n (%) 82 (13) NS 116 (13) <0.02 48 (8) <0.02
p<0.02
Patients with previous surgery and ankle-arm index less than 0.8
(n=139) (n=132) (n=48)
Cardiovascolar Events n (%) 26 (19) NS 23 (17) NS 6 (12) NS
NS
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Figure 1.  Fibrinogen plasma levels (Panel A), WBC count
(Panel B) and total cholesterol serum levels in North
(n=649), Middle (n=885) and South (n=577) of Italy.  
Symbols utilized in the Figures: *, p<0.01 (Mann-Whitney
U test), z min max;  cCL: 25%-75%;  K Median value
Fi
br
in
og
en
 (
m
g/
dL
)
To
ta
l l
eu
ko
cy
te
 c
ou
nt
 
(x
1
0
9
ce
lls
)
To
ta
l c
ho
le
st
er
ol
 
(m
g/
dL
)
diet rich in ω-3 fatty acids reduces fibrinogen.23 In the
south of Italy the diet is particularly rich in fish, but it
cannot be excluded that other dietary components
may also play a role. Another possibility is that the
variation of fibrinogen genotype which can be detect-
ed in PVD patients and is associated with higher
fibrinogen values,24 is less represented in the south of
Italy. In this study we did not seek to analyze whether
alcoholism might influence the regional distribution
of fibrinogen. However, to our knowledge, there is no
information available in our country suggesting that
alcohol abuse is more prevalent in the north and mid-
dle Italy than the south of Italy. Since the initial
hypothesis of the ADEP trial was not addressed to
evaluate the concentration of fibrinogen in the 3 geo-
graphic parts of Italy, a potential limitation of our
finding is that it results from a post-hoc analysis. How-
ever, the demonstration that more than one risk fac-
tor for atherosclerosis has a different geographic dis-
tribution could support the demonstration that
fibrinogen concentration is lower in the south than in
other areas of Italy.
Thus, WBC count and serum cholesterol levels were
not uniformly distributed as shown by the fact that
both were more frequently elevated in the north than
middle and south of Italy. This data raises the ques-
tion as to whether such non homogeneous prevalence
of risk factors may account for different rates of car-
diovascular diseases in PVD populations. In fact, two
large trials which used the same inclusion criteria,
demonstrated that claudicant patients have a large
variability in terms of annual rate of cardiovascular
events, which in fact ranged from 11 to 17%.7,25 Our
report may offer a possible explanation for this dis-
crepancy, since we found that a PVD population has
a non homogeneous distribution of risk factors with
a lower prevalence of risk factors in the south of Italy.
We do not have conclusive data to affirm that this
finding accounts for a different cardiovascular risk, in
part because the rate of events examined was low.
However, it is noteworthy that the annual rate of car-
diovascular events was lower in the south (12%) than
the middle (17%) and north (19%) of Italy.  Future tri-
als in PVD subjects should, therefore, take these data
into careful consideration, particularly in the case of
interventional studies.
In conclusion, this study shows that in a popula-
tion of patients with PVD, fibrinogen values are sig-
nificantly associated with WBC count and serum
cholesterol. Conversely, there is no significant asso-
ciation with the severity of PVD. The independent
association between areas of Italy and fibrinogen also
suggests that some not yet identified factors affect
fibrinogen. Identification of these factors could be
useful to plan strategy for reducing fibrinogen levels.
Finally, our findings raise the question as to whether
the large variability of cardiovascular events so far
reported in PVD is related to a different distribution
of risk factors.
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